Intelligent Bio Solutions Completes Clinical Study for FDA 510(k) Submission
NEW YORK, August 11, 2026 Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for...
phage therapy
Advertisement
SNIPR Advances SNIPR001 With Compassionate-Use Clinical Evidence
COPENHAGEN, Denmark, August 12, 2026 SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced...
Armata Secures $2.5M DoD Funding for AP-SA02
LOS ANGELES, Calif. | June 23, 2026 Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from...
Armata Pharmaceuticals Launches Advanced cGMP Phage Plant
Los Angeles, California, November 10, 2025 — Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company pioneering bacteriophage (phage) therapeutics targeting...
Armata Announces Phase 2a Success for S. aureus Phage Therapy
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
Advertisement
